Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 5/20 | 0.53 |
| ▸ | CHRND | Q07001 | 5/20 | 0.51 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.51 |
| ▸ | CHRNG | P07510 | 1/20 | 0.51 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.51 |
| ▸ | CD40 | P25942 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16976066 | 0.99 | GRIA1 (0.54) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL16976110 | 0.95 | GRIA1 (0.54) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL14479395 | 0.94 | GRIA1 (0.55) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL14479320 | 0.94 | GRIA1 (0.55) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL16976102 | 0.93 | GRIA1 (0.54) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL15185963 | 0.93 | GRIA1 (0.54) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL16976122 | 0.93 | GRIA1 (0.54) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL14479361 | 0.93 | GRIA1 (0.54) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL16976117 | 0.93 | GRIA1 (0.54) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL16976104 | 0.93 | GRIA1 (0.54) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9155795-B2 | CXCR4 receptor compounds | ANCHOR THERAPEUTICS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20130005944-A1 | CXCR4 Receptor Compounds | ACER THERAPEUTICS INC. | 2013-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005944-A1 | CXCR4 Receptor Compounds | CXCL12, CXCR4, CCR5 | GRIA1 561/4885CHRND 412/4885CHRNA1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.